140 related articles for article (PubMed ID: 36273268)
41. Subcellular immunolocalization of protein kinase CK2 in normal and carcinoma cells.
Faust RA; Niehans G; Gapany M; Hoistad D; Knapp D; Cherwitz D; Davis A; Adams GL; Ahmed K
Int J Biochem Cell Biol; 1999 Sep; 31(9):941-9. PubMed ID: 10533285
[TBL] [Abstract][Full Text] [Related]
42. Protein kinase casein kinase 2 mediates inhibitor-kappaB kinase and aberrant nuclear factor-kappaB activation by serum factor(s) in head and neck squamous carcinoma cells.
Yu M; Yeh J; Van Waes C
Cancer Res; 2006 Jul; 66(13):6722-31. PubMed ID: 16818647
[TBL] [Abstract][Full Text] [Related]
43. Casein kinase II (CK2) enhances death-inducing signaling complex (DISC) activity in TRAIL-induced apoptosis in human colon carcinoma cell lines.
Izeradjene K; Douglas L; Delaney A; Houghton JA
Oncogene; 2005 Mar; 24(12):2050-8. PubMed ID: 15688023
[TBL] [Abstract][Full Text] [Related]
44. Acetyl-CoA carboxylase rewires cancer metabolism to allow cancer cells to survive inhibition of the Warburg effect by cetuximab.
Luo J; Hong Y; Lu Y; Qiu S; Chaganty BK; Zhang L; Wang X; Li Q; Fan Z
Cancer Lett; 2017 Jan; 384():39-49. PubMed ID: 27693630
[TBL] [Abstract][Full Text] [Related]
45. Synergistic Interactions of 5-Fluorouracil with Inhibitors of Protein Kinase CK2 Correlate with p38 MAPK Activation and FAK Inhibition in the Triple-Negative Breast Cancer Cell Line.
Wińska P; Karatsai O; Staniszewska M; Koronkiewicz M; Chojnacki K; Rędowicz MJ
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872257
[TBL] [Abstract][Full Text] [Related]
46. Casein kinase 2 inhibitor CX-4945 elicits an anti-Warburg effects through the downregulation of TAp73 and inhibits gastric tumorigenesis.
Tang S; Yuan Y; Liu Z; He Y; Pan D
Biochem Biophys Res Commun; 2020 Oct; 530(4):686-691. PubMed ID: 32771361
[TBL] [Abstract][Full Text] [Related]
47. Coumestrol from the national cancer Institute's natural product library is a novel inhibitor of protein kinase CK2.
Liu S; Hsieh D; Yang YL; Xu Z; Peto C; Jablons DM; You L
BMC Pharmacol Toxicol; 2013 Jul; 14():36. PubMed ID: 23845105
[TBL] [Abstract][Full Text] [Related]
48. Casein Kinase II (CK2) as a Therapeutic Target for Hematological Malignancies.
Gowda C; Sachdev M; Muthusami S; Kapadia M; Petrovic-Dovat L; Hartman M; Ding Y; Song C; Payne JL; Tan BH; Dovat S
Curr Pharm Des; 2017; 23(1):95-107. PubMed ID: 27719640
[TBL] [Abstract][Full Text] [Related]
49. Chemically induced degradation of CK2 by proteolysis targeting chimeras based on a ubiquitin-proteasome pathway.
Chen H; Chen F; Liu N; Wang X; Gou S
Bioorg Chem; 2018 Dec; 81():536-544. PubMed ID: 30245235
[TBL] [Abstract][Full Text] [Related]
50. Mechanism and efficacy of sub-50-nm tenfibgen nanocapsules for cancer cell-directed delivery of anti-CK2 RNAi to primary and metastatic squamous cell carcinoma.
Unger GM; Kren BT; Korman VL; Kimbrough TG; Vogel RI; Ondrey FG; Trembley JH; Ahmed K
Mol Cancer Ther; 2014 Aug; 13(8):2018-29. PubMed ID: 24867250
[TBL] [Abstract][Full Text] [Related]
51. The synergistic therapeutic effect of imatinib and protein kinase CK2 Inhibition correlates with PI3K-AKT activation in gastrointestinal stromal tumors.
Zhou L; Wang H; Liu H; Huang Z; Wang Z; Zhou X; Mu X
Clin Res Hepatol Gastroenterol; 2022; 46(6):101886. PubMed ID: 35183792
[TBL] [Abstract][Full Text] [Related]
52. Regulation of the proapoptotic functions of prostate apoptosis response-4 (Par-4) by casein kinase 2 in prostate cancer cells.
de Thonel A; Hazoumé A; Kochin V; Isoniemi K; Jego G; Fourmaux E; Hammann A; Mjahed H; Filhol O; Micheau O; Rocchi P; Mezger V; Eriksson JE; Rangnekar VM; Garrido C
Cell Death Dis; 2014 Jan; 5(1):e1016. PubMed ID: 24457960
[TBL] [Abstract][Full Text] [Related]
53. ER stress signaling in ARPE-19 cells after inhibition of protein kinase CK2 by CX-4945.
Intemann J; Saidu NE; Schwind L; Montenarh M
Cell Signal; 2014 Jul; 26(7):1567-75. PubMed ID: 24686080
[TBL] [Abstract][Full Text] [Related]
54. Identification of Candidate Casein Kinase 2 Substrates in Mitosis by Quantitative Phosphoproteomics.
Rusin SF; Adamo ME; Kettenbach AN
Front Cell Dev Biol; 2017; 5():97. PubMed ID: 29214152
[TBL] [Abstract][Full Text] [Related]
55. CK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules.
Brown MS; Diallo OT; Hu M; Ehsanian R; Yang X; Arun P; Lu H; Korman V; Unger G; Ahmed K; Van Waes C; Chen Z
Clin Cancer Res; 2010 Apr; 16(8):2295-307. PubMed ID: 20371694
[TBL] [Abstract][Full Text] [Related]
56. Casein kinase 2 inhibition impairs spontaneous and oxytocin-induced contractions in late pregnant mouse uterus.
Suhas KS; Parida S; Gokul C; Srivastava V; Prakash E; Chauhan S; Singh TU; Panigrahi M; Telang AG; Mishra SK
Exp Physiol; 2018 May; 103(5):621-628. PubMed ID: 29708304
[TBL] [Abstract][Full Text] [Related]
57. Coordinated targeting of CK2 and KIT in gastrointestinal stromal tumours.
Huang M; Yang W; Zhu J; Mariño-Enríquez A; Zhu C; Chen J; Wu Y; Quan Y; Qiu H; Li X; Chai L; Fletcher JA; Ou WB
Br J Cancer; 2020 Feb; 122(3):372-381. PubMed ID: 31776458
[TBL] [Abstract][Full Text] [Related]
58. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
59. Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines.
Ma Y; Sender S; Sekora A; Kong W; Bauer P; Ameziane N; Krake S; Radefeldt M; Al-Ali R; Weiss FU; Lerch MM; Parveen A; Zechner D; Junghanss C; Murua Escobar H
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457227
[TBL] [Abstract][Full Text] [Related]
60. Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling.
Buontempo F; Orsini E; Martins LR; Antunes I; Lonetti A; Chiarini F; Tabellini G; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Cappellini A; Barata JT; Martelli AM
Leukemia; 2014 Mar; 28(3):543-53. PubMed ID: 24253024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
